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103 Effect of N-butyldeoxynojirimycin on chloride efﬂux from CF
airway epithelial cells
I. Oliynyk1, G.M. Roomans1. 1School of Health and Medical Sciences, O¨rebro
University, O¨rebro, Sweden
Using patch-clamp studies, the a-glucosidase inhibitor N-butyldeoxynojirimycin
(miglustat) has been shown to restore cAMP-dependent chloride current in hu-
man nasal epithelial, tracheal gland serous, and pancreatic duct cell lines de-
rived from DF508-homozygous CF-patients (Norez et al., FEBS Letters 580,
2006, 2081–2086). In the present study we have determined the effect of
N-butyldeoxynojirimycin on chloride efﬂux from human bronchial epithelial cells,
using the ﬂuorescent probe MQAE.
Non-CF (16HBE) and CF (CFBE) bronchial epithelial cells were cultured under
standard conditions in M199 medium at 37ºC. The cells were loaded with MQAE
for 2 h, and subsequently exposed to 100mM N-butyldeoxynojirimycin for 4 h. After
that, chloride efﬂux was determined from the decrease of the MQAE ﬂuorescence,
when the cells were exposed to a solution in which all chloride was replaced by
nitrate.
N-butyldeoxynojirimycin caused a 150% increase in chloride efﬂux from CFBE
cells (p = 0.006), in the absence of cAMP-elevating agents. No signiﬁcant effect
of N-butyldeoxynojirimycin was observed in non-CF 16HBE cells, in which the
chloride efﬂux in the absence of cAMP-elevating agents is about four times larger.
These results conﬁrm that N-butyldeoxynojirimycin can partially correct the defec-
tive chloride efﬂux in CF airway epithelial cells.
104 Flavonoides increase chloride conductance at the apical
membrane of the respiratory epithelium in some CF-patients
C. Geidel1, C. Rueckes-Nilges1, S. Klahr1, J. Burmeister1, K. Weber1,
D. Schueler1, R. Schulz1, H. Lindemann1, K.P. Zimmer1. 1CF-Center, Center of
Pediatrics and Youth medicine, Giessen, Germany
Flavonoides (FL) interact directly with the nucleotide binding domain 2 to stabilize
the open channel conﬁguration of CFTR and improve in vitro and in vivo the
permeability of CFTR dependent chloride channels in a part of the cystic ﬁbrosis
(CF) patients. We investigated the changes in chloride permeability during a therapy
with FL over 2 years.
With 29 CF-patients (7−44 y.) (mostly DF508/DF508), the nasal potential difference
(PD) was determined by means of superfusion method before and under amiloride
(blocking the epithelial sodium channel), under chloride-free solution (activation
of alternative chloride channels) and under salbutamole (stimulation of CFTR
dependent chloride channels). Afterwards for 24 months FL were given orally
(Crataegutt novo: <10 y.: 450mg/qd and >10 y.: 450mg/q12 h) and the PD was
repeated after 3, 6, 12 and 24 months.
The initial values of the PD, as well as the PD under blocking the sodium
channels and chloride-free solution were not signiﬁcantly changed before and
after systemic application of the FL. Under salbutamole superfusion after 6 and
12 months of FL there was seen a signiﬁcant improvement in repolarization of the
PD (p = 0.003/0.03). In 13 patients the PD increased 20%.
month repolarization after salbutamole(%) standard-dev. patients p value
0 −11.07 14.9 n = 29
3 9.16 5.78 n = 20 n.s
6 18.13 5.01 n = 14 0.003
12 16.53 8.37 n = 10 0.03
24 35.05 15.52 n = 6 n.s
Systemically given ﬂavonoids affect CFTR dependent chloride channels in a part
of the CF-patients positively and this effect seems to be stable over a period of
2 years.
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Rationale: This study assessed the efﬁcacy and safety of a new formulation
(inhalation powder) of tobramycin for treating chronic Pa infection in inhaled anti-
Pa antibiotic naive CF patients.
Methods: Patients 6−21 years, FEV1 25%-80% predicted (%pred) were ran-
domized 1:1 to double-blind treatment with tobramycin 112mg bid (n = 46) or
placebo (PBO; n = 49) administered via the T-326 DPI for 1 cycle, followed by 2
open-label cycles of tobramycin (all patients). Cycles were 28 days on, 28 days
off treatment. Primary endpoint was relative change in FEV1%pred from baseline
to Day 28 of Cycle 1. Other assessments included FVC and FEF25−75%pred,
respiratory-related hospitalizations, anti-Pa antibiotic use, sputum Pa density and
safety.
Results: At Day 28 of Cycle 1, tobramycin signiﬁcantly improves FEV1%pred vs
PBO (difference 13.3, 95%CI 5.31, 21.28; p = 0.0016). In patients switching from
PBO to tobramycin after Cycle 1, the relative change in FEV1%pred increases
to and is maintained at the level observed with tobramycin in Cycle 1. FVC
and FEF25−75 show similar results. Tobramycin decreases respiratory-related
hospitalization and other anti-Pa antibiotic use vs PBO, and reduces sputum Pa
density by about 2-log10 CFU from baseline at the end of dosing in each cycle.
Most common AEs reported were cough, pulmonary exacerbation and sore throat.
Conclusions: Tobramycin inhalation powder signiﬁcantly improves lung function,
decreases respiratory-related hospitalization and other anti-Pa antibiotic use vs PBO
in CF patients with chronic Pa infection, and overall is well tolerated.
Supported by: Novartis
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Introduction: During the last years twice daily (b.i.d.) inhalation of TOBI™
(300mg/5mL) in a 28-day on/off-dosing regimen has proven its safety and efﬁcacy
for the treatment of Pseudomonas aeruginosa (P.a.) in CF subjects. As some patients
do not tolerate off-phases continuous treatment with TOBI™ could provide an
additional beneﬁt.
Method: This multicenter, open label, two period cross-over study was designed
to generate ﬁrst interpretable pharmacokinetic (PK) data of 8 weeks continuous
treatment with 1×300mg/d and 2×300mg/d TOBI™ inhaled with the PARI
eFlow™ rapid. The study population does consist of 35 CF patients 6 years
chronically infected with P.a.. After a screening period the patients are randomized
to enter the ﬁrst 8 weeks treatment period with either o.d. or b.i.d. inhalation. PK
samples are taken after 4 and 8 weeks of inhalation. Following a 4 weeks wash-out
period, the patients enter the second treatment period with the alternative inhalation
regimen. Safety parameters are closely monitored throughout the study.
The key objectives of this study are to investigate the serum PK of tobramycin
(AUC0−90′ ) of continuous daily dosing b.i.d. and o.d.. Further objectives are safety
parameters, change of MIC of P.a., the effect on lung function and patient reported
outcomes and the comparison of these parameters between subpopulations.
Conclusion: The data obtained from this study could generate valuable insights
into PK and safety of continuous treatment with TOBI™ and will support planning
of future studies on alternative treatment regimens.
